RESUMO
Tumor growth and local invasion are greatly dependent on the malignant potential of a tumor cell, but are also significantly modulated by a variety of local factors. These factors comprise cytokines, growth factors and extracellular matrix proteins (ECM), which act through a complex system of auto-, para- and juxtacrine interactions. Some factors are produced by the malignant cell itself, others are expressed by adjacent tumor stroma, migrated inflammatory cells, or resident macrophages. We have investigated the influences of cytokines and growth factors known to be expressed by tumor stroma on the cytokine expression pattern of three human breast cancer cell lines of different malignant potential. MCF-7, T47D and MDA-MB-231 were incubated with human recombinant TNF-alpha, IGF-I, IGF-II, bFGF, HGF or G-CSF and the pattern of tumor-cell-derived TGF-beta1, bFGF, IL-1alpha and VEGF was analyzed. Among the three cell lines used we observed a heterogenous response to stromal cytokines by measuring above mentioned factors in the cell culture's supernatants, but no clear correlation between malignant potential and cytokine expression pattern seemed obvious. We hypothesize that local growth factors may have a significant modulatory effect on malignant behavior in vivo. We conclude that this effect might depend on individual responses and on the differentiation state of tumor cells.
Assuntos
Neoplasias da Mama/metabolismo , Citocinas/metabolismo , Substâncias de Crescimento/metabolismo , Neoplasias da Mama/patologia , Contagem de Células , Feminino , Humanos , Células Tumorais CultivadasRESUMO
An estimated 100 million individuals suffer from birch pollen allergy. Specific immunotherapy, the only curative allergy treatment, can cause life-threatening anaphylactic side effects. Here, we report the genetic engineering of a recombinant trimer consisting of three covalently linked copies of the major birch pollen allergen, Bet v 1. The trimer exhibited profoundly reduced allergenic activity but contained similar secondary structures such as Bet v 1 wild type, Bet v 1-specific B cell and T-cell epitopes, and induced Th1 cytokine release. As immunogen, rBet v 1 trimer induced IgG antibodies, which blocked patients' IgE binding to Bet v 1 and related allergens. Thus, rBet v 1 trimer represents a novel hypoallergenic vaccine prototype for treatment of one of the most frequent allergy forms.
Assuntos
Alérgenos/imunologia , Proteínas de Plantas/imunologia , Linfócitos T/imunologia , Alérgenos/genética , Antígenos de Plantas , Divisão Celular , Células Cultivadas , Citocinas/metabolismo , Epitopos de Linfócito B/imunologia , Epitopos de Linfócito T/imunologia , Engenharia Genética , Humanos , Imunoglobulina E/imunologia , Imunoglobulina G/imunologia , Proteínas de Plantas/genética , Proteínas Recombinantes/genética , Proteínas Recombinantes/imunologia , Linfócitos T/citologia , Células Th1/imunologiaAssuntos
Alérgenos/uso terapêutico , Dessensibilização Imunológica , Hipersensibilidade/tratamento farmacológico , Proteínas de Plantas/uso terapêutico , Proteínas Recombinantes/uso terapêutico , Alérgenos/genética , Alérgenos/imunologia , Antígenos de Plantas , Engenharia Genética , Humanos , Hipersensibilidade/imunologia , Proteínas de Plantas/genética , Proteínas de Plantas/imunologia , Pólen , Proteínas Recombinantes/genética , Proteínas Recombinantes/imunologiaRESUMO
The aim of this study was to evaluate the prevalence of simple sequence variation in the BRCA2 gene. To this end, 71 breast and breast-ovarian cancer (HBC/HBOC) families along with 95 control individuals from a wide range of ethnicities were analyzed by means of denaturing high-performance liquid chromatography (DHPLC) and direct sequence analysis. In the coding (10 257 bp) and non-coding (2799 bp) sequences of BRCA2, 82 sequence variants were identified. Three different, apparently disease-associated BRCA2 mutations were found in six HBC/HBOC families (8%): two splice site mutations in introns 5 and 21, and one frameshift mutation in exon 11. In the coding region, 53 simple sequence variants were found: 35 missense mutations, one 2 bp deletion (CT) resulting in a stop at codon 3364, one nonsense mutation with a stop at codon 3326, one deletion of a complete codon (AAA) resulting in the loss of leucine, and 15 silent mutations. In the non-coding region, 26 polymorphisms were detected. Of the 79 sequence variants that were not obviously disease-associated, eight were detected only in HBC/HBOC families. The remaining 71 variants were identified in both HBC/HBOC families and control individuals. Sixty three sequence variants (80%) were specific for a continent. Forty two percent (33 out of 79) of the sequence variants were detected exclusively in Africa, though only 13% of the 332 chromosomes screened were of African origin. Our data indicate that, in BRCA2, simple sequence variation is frequent [in the coding region 1 in 194 bp (straight theta = 2.2 x 10(-4)), and in the non-coding region 1 in 108 bp (straight theta = 4.4 x 10(-4)), respectively].
Assuntos
Neoplasias da Mama/genética , Genes Supressores de Tumor , Proteínas de Neoplasias/genética , Fatores de Transcrição/genética , África , Proteína BRCA2 , Sequência de Bases , Análise Mutacional de DNA , Primers do DNA/genética , Feminino , Frequência do Gene , Variação Genética , Humanos , Masculino , Mutação , Neoplasias Ovarianas/genética , LinhagemRESUMO
We identified 17 BRCA1 mutations in 86 Austrian breast and ovarian cancer families (20%) that were screened for mutations by denaturing high-performance liquid chromatography (DHPLC) and the protein truncation test (PTT). Eleven distinct mutations were detected, 4 of them (962del4, 2795del4, 3135del4 and L3376stop) not previously reported in families of non-Austrian origin. In addition, 6 rare missense mutations (allele frequency < 1%) with unknown biological effects were identified. Four mutations occurred more than once in the Austrian population: 2795del4 (3 times), Cys61Gly (3 times) 5382insC (2 times) and Q1806stop (2 times). Haplotype analysis of the 4 recurrent mutations suggested a common ancestor for each of these. Thirty-four breast cancer cases from 17 families with BRCA1 mutations were further analyzed. We observed a low median age of onset (39.5 years). Sixty-eight percent of all BRCA1 breast cancer cases had negative axillary lymph nodes. This group showed a significant prevalence of a negative estrogen and progesterone receptor status and stage I tumors compared with an age-related, node-negative control group. The prevalence of grade III tumors was marginally significant. Survival analysis either with a control group matched for age (within 5 years), grade, histologic subtype and estrogen receptor status, or with an age-related, node-negative comparison group, showed no statistical difference.
Assuntos
Neoplasias da Mama/genética , Genes BRCA1 , Mutação , Neoplasias Ovarianas/genética , Adulto , Áustria , Proteína BRCA1/química , Proteína BRCA1/genética , Neoplasias da Mama/mortalidade , Neoplasias da Mama/patologia , Carcinoma Ductal de Mama/genética , Carcinoma Lobular/genética , Carcinoma Medular/genética , Elementos de DNA Transponíveis , Família , Feminino , Mutação da Fase de Leitura , Humanos , Metástase Linfática , Pessoa de Meia-Idade , Invasividade Neoplásica , Estadiamento de Neoplasias , Mutação Puntual , Receptores de Estrogênio/análise , Receptores de Progesterona/análise , Recidiva , Deleção de Sequência , Taxa de SobrevidaRESUMO
We have expressed in Escherichia coli two halves of the major birch pollen allergen, Bet v 1. Both fragments representing the complete 17-kD allergen were purified to homogeneity. In contrast to the complete recombinant, Bet v 1, the fragments had almost completely lost their IgE-binding capacity and exhibited a random coil structure as analyzed by circular dichroism. The ability of the recombinant fragments to trigger histamine release from allergic patients' basophils as well as their capacity to elicit skin reactions were also largely abolished. Both non-anaphylactic Bet v 1 fragments carried the majority of T cell epitopes and may therefore be considered as safe tools for immunotherapy of tree pollen and associated food allergy.
Assuntos
Alérgenos/imunologia , Fragmentos de Peptídeos/imunologia , Proteínas de Plantas/imunologia , Antígenos de Plantas , Humanos , Imunoglobulina E/imunologia , Proteínas Recombinantes/imunologia , Linfócitos T/imunologiaRESUMO
A novel approach to reduce the anaphylactic activity of allergens is suggested. The strategy makes use of the presence of conformational immunoglobulin E (IgE) epitopes on one of the most common allergens. The three dimensional structure of the major birch pollen allergen, Bet v 1, was disrupted by expressing two parts of the Bet v 1 cDNA representing amino acids 1-74 and 75-160 in Escherichia coli. In contrast to the complete recombinant Bet v 1, the fragments showed almost no allergenicity and exhibited random coil conformation as analyzed by circular dichroism. Both nonanaphylactic fragments induced proliferation of human Bet v 1-specific T cell clones, indicating that they harbored all dominant T cell epitopes and therefore may be considered as a basis for the development of a safe and specific T cell immunotherapy.
Assuntos
Alérgenos , Epitopos , Hipersensibilidade/terapia , Fragmentos de Peptídeos/imunologia , Proteínas de Plantas/química , Linfócitos T/imunologia , Anafilaxia/prevenção & controle , Animais , Antígenos de Plantas , Dicroísmo Circular , Liberação de Histamina , Humanos , Imunoglobulina E/metabolismo , Imunoterapia , Camundongos , Proteínas de Plantas/imunologia , Proteínas de Plantas/isolamento & purificação , Conformação Proteica , Proteínas Recombinantes/isolamento & purificaçãoRESUMO
We dissected the T cell activation potency and the immunoglobulin (Ig) E-binding properties (allergenicity) of nine isoforms of Bet v 1 (Bet v 1a-Bet v 1l), the major birch pollen allergen. Immunoblot experiments showed that Bet v 1 isoforms differ in their ability to bind IgE from birch pollen-allergic patients. All patients tested displayed similar IgE-binding patterns toward each particular isoform. Based on these experiments, we grouped Bet v 1 isoforms in three classes: molecules with high IgE-binding activity (isoforms a, e, and j), intermediate IgE-binding (isoforms b, c, and f), and low/no IgE-binding activity (isoforms d, g, and 1). Bet v 1a, a recombinant isoform selected from a cDNA expression library using IgE immunoscreening exhibited the highest IgE-binding activity. Isoforms a, b, d, e, and 1 were chosen as representatives from the three classes for experimentation. The potency of each isoallergen to activate T lymphocytes from birch pollen-allergic patients was assayed using peripheral blood mononuclear cells, allergen-specific T cell lines, and peptide-mapped allergen-specific T cell clones. Among the patients, some displayed a broad range of T cell-recognition patterns for Bet v 1 isoforms whereas others seemed to be restricted to particular isoforms. In spite of this variability, the highest scores for T cell proliferative responses were observed with isoform d (low IgE binder), followed by b, 1, e, and a. In vivo (skin prick) tests showed that the potency of isoforms d and 1 to induce typical urticarial type 1 reactions in Bet v 1-allergic individuals was significantly lower than for isoforms a, b, and e. Taken together, our results indicate that hypoallergenic Bet v 1 isoforms are potent activators of allergen-specific T lymphocytes, and Bet v 1 isoforms with high in vitro IgE-binding activity and in vivo allergenicity can display low T cell antigenicity. Based on these findings, we propose a novel approach for immunotherapy of type I allergies: a treatment with high doses of hypoallergenic isoforms or recombinant variants of atopic allergens. We proceed on the assumption that this measure would modulate the quality of the T helper cell response to allergens in vivo. The therapy form would additionally implicate a reduced risk of anaphylactic side effects.